ANO1 and prostate cancer: Down-regulation of TMEM16A protein levels by RNAi and pharmacologic blockade decrease the proliferation of breast cancer, prostate cancer and HNSCC by affecting the activation of the MAPK/AKT signalling pathways [14,17].